Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

Stock Information for ObsEva

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ObsEva

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
ObsEva Announces Update on Board of Directors
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
Geneva Court Grants Temporary Moratorium to ObsEva
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
Organon Returns Ebopiprant to XOMA
ObsEva Files half Year 2023 Financial Statements
ObsEva Recovers Full Worldwide Rights on Nolasiban

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.